Protagenic Therapeutics- Warrants (13/04/2025) Operating Income

As of the most recent data (June 2026), PTIXW shows a operating income of $-4.3M. That compares with $-6.1M in the prior-year period — up 30.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PTIXW's operating income is now $-4.3M (was $-6.1M) — a 30.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Protagenic Therapeutics- Warrants (13/04/2025) is outperforming or lagging.

Tracking PTIXW's operating income over time shows whether Protagenic Therapeutics- Warrants (13/04/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $-4.3M That compares with $-6.1M in the prior-year period — up 30.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Protagenic Therapeutics- Warrants (13/04/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-4.3M) with ownership activity and broader fundamentals.

Protagenic Therapeutics- Warrants (13/04/2025)'s operating income is $-4.3M; compare it with other Industrials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.